Neurology

Supplements, such as Prevagen, as well as lifestyle and diet modifications can provide additional support to patients with Alzheimer disease.

Compared with other treatments for myasthenia gravis, nipocalimab demonstrated more significant improvements in disability scores, with tolerable safety.

Pregnant individuals with multiple sclerosis (MS) are more likely to experience mental illness both during their pregnancy and in the first years after giving birth.

The approval marks the first subcutaneous infusion device approved for the treatment of Parkinson disease, providing a new option for patients with serious disease who are unresponsive to other therapies.

Health care professionals, particularly pharmacists, can recommend that patients take over-the-counter supplements, such as melatonin, to facilitate REM sleep.

Meloxicam and rizatriptan reduces migraine pain and help patients return to normal functioning with efficacy through 24 to 48 hours after a single dose for some patients.

Administered every 4 weeks, the approval could serve as a breakthrough for easier and more effective care for patients with early Alzheimer disease.

Pharmacists bridge communication gaps and enhance shared decision-making.

Memantine/donepezil and everolimus are used to treat dementia of the Alzheimer type and tuberous sclerosis complex-associated subependymal giant cell astrocytoma, respectively.

Patients with multiple sclerosis being treated with glatiramer acetate have an increased risk of experiencing anaphylaxis.

These drugs are set to revolutionize their respective disease states in 2025.

The finding could help better treat patients with long COVID, as pharmacists and treatment providers can look out for ME/CFS symptoms.

Successfully integrating biosimilars into practices requires careful planning and execution, as they impact virtually all aspects of a practice.

Managing comorbidities, ensuring proper dosing, and treating IVIG-related adverse events are areas where pharmacists play a large role.

Hokkaido scallop oil plasmalogen and Apoaequorin have both been posited to improve brain health.

If approved, nipocalimab can treat antibody positive individuals with generalized myasthenia gravis.

The pharmacist’s role includes educating and making recommendations, collaborating with health care professionals, and observing early signs of cognitive impairment in patients during interactions.

Duchenne muscular dystrophy is an incurable neuromuscular disorder that can lead to cardiomyopathy, resulting in heart failure.

These inequalities, which can include socioeconomic disparities, show neurological changes associated with aging and dementia.

Researchers recommend early vaccination against herpes zoster to mitigate the risks.

Based on positive results from the HERCULES trial, the new designation will allow for more thorough regulatory review and development of the multiple sclerosis treatment.

Adults with epilepsy are underrepresented in most CBD trials, including common etiologies.

Children born moderate to late preterm also showed more behavior difficulties compared with those born early term or later.

Asthma onset earlier in childhood may be linked to more severe difficulties that could extend to executive function abilities.

Intravenous immunoglobulin (IVIG) has proven efficacy in autoimmune neuropathies, with mixed but promising outcomes in severe COVID-19 cases and post-acute sequelae of SARS-CoV-2 infection trials.

If approved, RAG-21 can offer improved outcomes in patients with amyotrophic lateral sclerosis (ALS), particularly those with aggressive subtypes.

Eladocagene exuparvovec-tneq is the first FDA-approved gene therapy for individuals with aromatic L-amino acid decarboxylase deficiency.

The study found that this patient population was about 25% more likely to have serious mental health issues after childbirth.

If approved, the investigational intravenous gene therapy will be the first disease-modifying therapy for developmental and epileptic encephalopathy (DEE).

The investigators found that the SRGAP2 and SYNGAP1 genes act together to control the speed of human synapse development, which has impacts on neurodevelopmental disease pathways.